HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Cys-ZHER2-342 affibody

targets HER2 protein

Also Known As:

ZHER2:342

Networked: 20 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - Cys-ZHER2-342 affibody: 20

Experts

1.	Orlova, Anna: 8 articles (01/2018 - 02/2007)
2.	Tolmachev, Vladimir: 7 articles (01/2018 - 02/2007)
3.	Karlström, Amelie Eriksson: 6 articles (01/2018 - 03/2007)
4.	Altai, Mohamed: 5 articles (01/2018 - 04/2013)
5.	Westerlund, Kristina: 4 articles (01/2018 - 01/2016)
6.	Mitran, Bogdan: 3 articles (01/2018 - 11/2017)
7.	Cheng, Zhen: 2 articles (10/2019 - 07/2012)
8.	Honarvar, Hadis: 2 articles (11/2017 - 01/2016)
9.	Hou, Yanglong: 2 articles (01/2017 - 06/2014)
10.	Li, Gongjie: 2 articles (01/2017 - 06/2014)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2007 - "Preclinical and pilot clinical studies have demonstrated the utility of radiolabeled ZHER2:342 in imaging of HER2-expressing tumors. " 10/01/2019 - "Although varied in the position of the radiometal labeling of these three Cu-64-labeled ZHER2:342 analogues, there is no significant difference in tumor and normal tissue uptakes among the three probes. " 10/01/2019 - "The three Cu-64-labeled ZHER2:342 analogues all display excellent HER2 targeting ability and tumor PET imaging quality. " 01/01/2018 - "Tumor uptake of 68Ga-HP2 correlated better with the uptake of 177Lu-HP2 than the uptake of 68Ga-ZHER2:342-SR-HP1. " 01/01/2018 - "The uptake of both 68Ga-ZHER2:342-SR-HP1 and 68Ga-HP2 depended on Her2-expression level providing clear discrimination of between tumors with high and low Her2 expression. "
2.	Neoplasm Metastasis (Metastasis) 04/01/2013 - "Radiolabeled subnanomolar anti-HER2 affibody ZHER2:342 was developed for imaging of HER2 expression in tumors, and a clinical study has demonstrated that the (111)In- and (68)Ga-labeled affibody molecules can efficiently detect HER2 expressing metastases in breast cancer patients. " 06/01/2012 - "PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG."
3.	Carcinoma (Carcinomatosis) 10/01/2019 - "Cell uptake assay of the resulting PET probes, [64Cu]DOTA-Cys-ZHER2:342, [64Cu]DOTA-ZHER2:342(Cys39), and [64Cu]DOTA-ZHER2:342-Cys, was performed in HER2-positive human ovarian SKOV3 carcinoma cells at 4 and 37 °C. " 02/01/2007 - "Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma."
4.	Breast Neoplasms (Breast Cancer) 04/01/2013 - "Radiolabeled subnanomolar anti-HER2 affibody ZHER2:342 was developed for imaging of HER2 expression in tumors, and a clinical study has demonstrated that the (111)In- and (68)Ga-labeled affibody molecules can efficiently detect HER2 expressing metastases in breast cancer patients. " 06/01/2012 - "PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG."
5.	Stomach Neoplasms (Stomach Cancer) 04/03/2019 - "Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe."

Related Drugs and Biologics

1.	silicon phthalocyanine
2.	Molecular Probes (Molecular Probe)
3.	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononane
4.	Trp-cage peptide
5.	Proteins (Proteins, Gene)
6.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
7.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
8.	Peptides (Polypeptides)
9.	Ligands
10.	Fatty Acids (Saturated Fatty Acids)

Related Therapies and Procedures

1.	Therapeutics
2.	Gamma Cameras (Gamma Camera)
3.	Lasers (Laser)